Drug Res (Stuttg) 2021; 71(S 01): S7
DOI: 10.1055/a-1606-5411
Extended Abstract

Drug-Induced Liver Injury (DILI): A Major Challenge

Drug-induced liver injury (DILI) is the most common cause for acute liver failure in the USA and Europe. DILI is also a leading cause of attrition of compounds in drug development and one of the two most frequent causes for drug withdrawals, restrictions, and project terminations. Whereas liver signals that escape detection during drug approval result in postmarketing restrictions (e. g., pazopanib, temozolomide and flupirtine in 2013), the risk of false-positive DILI adjudication may lead to unnecessary attrition, thereby contributing to the considerable economic issues associated with DILI [1].

Publication History

Publication Date:
17 November 2021 (online)

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany